ラグノスＮＦ経口ゼリー分包１２ｇ ５４．１６７％
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00581 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 79 |
| 日本商品名（例） | ラグノスＮＦ経口ゼリー分包１２ｇ ５４．１６７％ |
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | acute urate nephropathy | 99% | DL |
| 2 | nephrolithiasis | 99% | DL |
| 3 | obstructive jaundice | 99% | DL |
| 4 | bile duct disease | 99% | DL |
| 5 | biliary tract disease | 99% | DL |
| 6 | hyperphosphatemia (disease) | 99% | DL |
| 7 | exercise-induced malignant hyperthermia | 99% | DL |
| 8 | bile duct neoplasm | 99% | DL |
| 9 | iron deficiency anemia | 98% | DL |
| 10 | opiate dependence | 98% | DL |
| 11 | nephrolithiasis susceptibility caused by SLC26A1 | 98% | DL |
| 12 | cholelithiasis | 98% | DL |
| 13 | urolithiasis | 98% | DL |
| 14 | familial visceral myopathy | 98% | DL |
| 15 | periodic paralysis (disease) | 98% | DL |
| 16 | malignant hyperthermia, susceptibility to | 98% | DL |
| 17 | gallstones | 97% | DL |
| 18 | X-linked centronuclear myopathy | 97% | DL |
| 19 | familial periodic paralysis | 97% | DL |
| 20 | hypokalemic periodic paralysis | 97% | DL |
| 21 | cholestasis, intrahepatic, of pregnancy | 97% | DL |
| 22 | central core myopathy | 97% | DL |
| 23 | congestive heart failure | 97% | DL |
| 24 | moderate multiminicore disease with hand involvement | 97% | DL |
| 25 | congenital multicore myopathy with external ophthalmoplegia | 97% | DL |
| 26 | xerophthalmia | 97% | DL |
| 27 | tumoral calcinosis, hyperphosphatemic, familial | 96% | DL |
| 28 | acute pulmonary heart disease | 96% | DL |
| 29 | deficiency anemia | 96% | DL |
| 30 | hypoglycemia | 96% | DL |
| 31 | morphine dependence | 95% | DL |
| 32 | apical periodontitis | 95% | DL |
| 33 | progressive familial intrahepatic cholestasis | 95% | DL |
| 34 | thyrotoxic periodic paralysis | 95% | DL |
| 35 | renal tubular acidosis | 95% | DL |
| 36 | periapical granuloma | 95% | DL |
| 37 | suppurative periapical periodontitis | 95% | DL |
| 38 | hereditary angioedema with C1Inh deficiency | 95% | DL |
| 39 | thyrotoxic periodic paralysis, susceptibility to | 95% | DL |
| 40 | King-Denborough syndrome | 95% | DL |
| 41 | familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome | 95% | DL |
| 42 | hepatic encephalopathy | 94% | DL |
| 43 | intestinal obstruction | 94% | DL |
| 44 | hypouricemia, renal | 94% | DL |
| 45 | unclassified intestinal pseudoobstruction | 94% | DL |
| 46 | myopathic intestinal pseudoobstruction | 94% | DL |
| 47 | idiopathic eosinophilic myositis | 94% | DL |
| 48 | inflammatory myopathy with abundant macrophages | 94% | DL |
| 49 | nephrolithiasis, X-linked recessive, with renal failure | 94% | DL |
| 50 | myopathy, centronuclear | 94% | DL |
（上位50件を表示。全79件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。